1st Circ. Finds No Fraud In Ocular Therapeutix Stock Suit
Biotech company Ocular Therapeutix didn't intentionally mislead investors in conference calls and filings about manufacturing problems that led to the U.S. Food and Drug Administration twice denying its steroid treatment for...To view the full article, register now.
Already a subscriber? Click here to view full article